Back to Search Start Over

Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France

Authors :
Lubomira Andrew
Julio Cesar Hawkins
Kathrin U. Jansen
Muhamed-Kheir Taha
Annaliesa S. Anderson
Ala-Eddine Deghmane
Li Hao
Lisa K. McNeil
John L. Perez
Paul A. Liberator
Thomas R. Jones
Robert E. O’Neill
Infections Bactériennes Invasives
Institut Pasteur [Paris]
Pfizer
This study was funded by Pfizer Inc, which also funded the development and publication costs for the present manuscript. The presented work is the product of a research collaboration between Pfizer Inc and the Institut Pasteur (Paris, France). The Institut Pasteur provided the isolates, both Institut Pasteur and Pfizer contributed to strain characterization, and Pfizer performed MEASURE and exploratory hSBA assays. Pfizer provided funding to Institut Pasteur to process the isolates.
Institut Pasteur [Paris] (IP)
Source :
Vaccine, Vaccine, Elsevier, 2017, 35 (11), pp.1530-1537. ⟨10.1016/j.vaccine.2017.01.066⟩, Vaccine, 2017, 35 (11), pp.1530-1537. ⟨10.1016/j.vaccine.2017.01.066⟩
Publication Year :
2016

Abstract

International audience; OBJECTIVES:Bivalent rLP2086 (Trumenba®; MenB-FHbp), composed of two factor H binding proteins (FHbps), is a vaccine approved in the United States for prevention of Neisseria meningitidis serogroup B (MnB) invasive meningococcal disease (IMD). Bactericidal activity of sera from subjects vaccinated with bivalent rLP2086 was assessed against MnB isolates from recent disease outbreaks in France.METHODS:MnB isolates from IMD cases were characterized by whole genome sequencing and FHbp expression was assessed using a flow cytometry-based assay. Sera from subjects (11

Subjects

Subjects :
0301 basic medicine
Male
Bivalent rLP2086
Neisseria meningitidis, Serogroup B
MESH: Meningococcal Vaccines
Disease Outbreaks
0302 clinical medicine
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
MESH: Child
030212 general & internal medicine
MESH: Disease Outbreaks
Child
MESH: Bacterial Proteins
MESH: Microbial Viability
Neisseria meningitidis serogroup B
Mean fluorescence intensity
MESH: Blood Bactericidal Activity
3. Good health
Vaccination
Infectious Diseases
Invasive meningococcal disease
Molecular Medicine
Female
France
Blood Bactericidal Activity
Adolescent
030106 microbiology
MESH: Complement System Proteins
Meningococcal Vaccines
Biology
Bivalent (genetics)
Microbiology
MenB-FHbp
03 medical and health sciences
MESH: Gene Expression Profiling
Immune system
Bacterial Proteins
MESH: Neisseria meningitidis, Serogroup B
Humans
MESH: Adolescent
Antigens, Bacterial
MESH: Humans
Microbial Viability
General Veterinary
General Immunology and Microbiology
Gene Expression Profiling
Public Health, Environmental and Occupational Health
Outbreak
Complement System Proteins
Virology
MESH: Male
MESH: France
Factor H binding protein
[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
MESH: Female
MESH: Antigens, Bacterial

Details

ISSN :
18732518 and 0264410X
Volume :
35
Issue :
11
Database :
OpenAIRE
Journal :
Vaccine
Accession number :
edsair.doi.dedup.....93b429af78c34d248f044c005ca43c20
Full Text :
https://doi.org/10.1016/j.vaccine.2017.01.066⟩
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details